Curi Bio, Inc.

Curi Bio develops human iPSC-based products, services, and integrated research platforms for drug discovery and preclinical development. Its human-derived cardiac, skeletal muscle, neuromuscular, and disease models combine 2D and 3D tissue systems with biosystems for functional analysis and data analytics, including AI/ML-enabled insights. The company’s platforms support research into therapeutic discovery, safety, efficacy, and potency.